WO2022118947A1 - 抗体を測定する方法およびキット - Google Patents

抗体を測定する方法およびキット Download PDF

Info

Publication number
WO2022118947A1
WO2022118947A1 PCT/JP2021/044427 JP2021044427W WO2022118947A1 WO 2022118947 A1 WO2022118947 A1 WO 2022118947A1 JP 2021044427 W JP2021044427 W JP 2021044427W WO 2022118947 A1 WO2022118947 A1 WO 2022118947A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
test animal
reagent
immunoglobulin
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2021/044427
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
貴洋 村上
幸弘 吉田
曜 櫓
宜聖 高橋
彩野 森山
忠樹 鈴木
英嗣 藤垣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujita Health University
National Institute of Infectious Diseases
Fujifilm Wako Pure Chemical Corp
Original Assignee
Fujita Health University
National Institute of Infectious Diseases
Fujifilm Wako Pure Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujita Health University, National Institute of Infectious Diseases, Fujifilm Wako Pure Chemical Corp filed Critical Fujita Health University
Priority to JP2022566997A priority Critical patent/JPWO2022118947A1/ja
Publication of WO2022118947A1 publication Critical patent/WO2022118947A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Definitions

  • the present invention relates to a method and a kit for measuring an antibody in a biological sample.
  • Hepatitis B virus antibody and chlamydia antibody are known for measuring antibodies against viruses, bacteria and parasites
  • rheumatoid factor and thyroid peroxidase antibody are known for measuring autoantibodies.
  • An object of the present invention is to provide an antibody measuring method and an antibody measuring kit in which false low values and false negatives are reduced in the measurement of a test animal antibody contained in a biological sample of a test animal. Further, more specifically, it is an object of the present invention to provide an antibody measuring method and an antibody measuring kit having an improved correlation with a neutralizing antibody.
  • the present invention includes the following inventions in order to solve the above problems.
  • a method for measuring a test animal antibody contained in a biological sample of a test animal in which the antigen and the biological sample of the test animal are brought into contact with an anti-test animal immunoglobulin antibody, and the antigen and the test are tested.
  • the anti-test animal immunoglobulin antibody comprises measuring a complex of an animal antibody and an anti-test animal immunoglobulin antibody, wherein the anti-test animal immunoglobulin antibody is a plurality of antibodies against a particular class of immunoglobulin, said particular class.
  • a method comprising an antibody that cross-reacts with immunoglobulins of all subclasses of.
  • the anti-test animal immunoglobulin antibody further comprises an antibody that specifically reacts with an immunoglobulin of a specific subclass of the same class as the specific class.
  • the particular class of immunoglobulin is IgG.
  • the test animal antibody is an antibody against non-self or an autoantibody.
  • the non-self is a pathogenic microorganism, a virus or a parasite.
  • the method according to [5] above, wherein the non-self is a virus.
  • a kit comprising a plurality of antibodies against an immunoglobulin of the above, comprising an antibody that cross-reacts with all subclasses of the immunoglobulin of the particular class.
  • the anti-test animal immunoglobulin antibody further comprises an antibody that specifically reacts with an immunoglobulin of a specific subclass of the same class as the specific class.
  • the particular class of immunoglobulin is IgG.
  • the antigen is a viral antigen.
  • the viral antigen is a fragment of a peaplomer of SARS-CoV-2.
  • the plurality of antibodies are anti-test animal immunoglobulin antibodies belonging to different subclasses of the specific class.
  • an antibody measuring method and an antibody measuring kit in which false low values and false negatives are reduced in the measurement of a test animal antibody contained in a biological sample of a test animal. Further, according to the present invention, more specifically, it is possible to provide an antibody measuring method and an antibody measuring kit having an improved correlation with a neutralizing antibody.
  • the antibody concentration against SARS-CoV-2 S-RBD and the neutralization activity value against SARS-CoV-2 were measured for the sera of 34 cases collected from COVID-19 patients, respectively, and the correlation between the two was shown.
  • the third reagent A containing only the antibody recognizing all subclasses of human IgG as the detection antibody reagent used in (A) for measuring the antibody concentration
  • (B) is for detection used in measuring the antibody concentration.
  • the third reagent B containing only the antibody specifically recognizing human IgG4 as the antibody reagent (C) the third reagent C containing both the antibody of the third reagent A and the antibody of the third reagent B. It is a result when.
  • the antibody concentration against SARS-CoV-2 S-RBD and the neutralization activity value against SARS-CoV-2 were measured for the sera of 34 cases collected from COVID-19 patients, respectively, and the correlation between the two was shown.
  • the third reagent A containing only the antibody recognizing all subclasses of human IgG as the detection antibody reagent used in (A) for measuring the antibody concentration
  • (B) is for detection used in measuring the antibody concentration.
  • the third reagent D containing only the antibody specifically recognizing human IgG3 as the antibody reagent
  • the third reagent E containing both the antibody of the third reagent A and the antibody of the third reagent D. It is a result when.
  • Antibodies to SARS-CoV-2 Spike protein measured by ELISA using a SARS-CoV-2 Spike protein-immobilized plate and neutralization to SARS-CoV-2 in 34 sera collected from COVID-19 patients. It is a figure showing the correlation with the activity value, and as a result of the case where (A) uses only an antibody that recognizes all subclasses of human IgG as an enzyme-labeled antibody, (B) is all subclasses of human IgG as an enzyme-labeled antibody. This is the result when a mixture of an antibody that recognizes human IgG3 and an antibody that specifically recognizes human IgG3 is used.
  • the present invention provides a method for measuring a test animal antibody contained in a biological sample of a test animal (hereinafter referred to as "the measuring method of the present invention").
  • the measuring method of the present invention comprises contacting the antigen with a biological sample of the test animal and the anti-test animal immunoglobulin antibody (step 1), and the antigen, the test animal antibody, and the anti-test animal immunoglobulin antibody.
  • a method comprising the step of measuring a complex (step 2), characterized in that the anti-test animal immunoglobulin antibody is a plurality of antibodies against a particular class of immunoglobulin.
  • the test animal may be an animal having an adaptive immune system.
  • the test animal may be a mammal, and examples thereof include humans, non-human primates, rabbits, guinea pigs, rats, mice, dogs, cats, horses, cows, pigs, sheep, and goats. It is preferably human.
  • the biological sample is not particularly limited as long as it is a sample in which the antibody of the test animal can be present, and examples thereof include blood, body fluid, and tissue. Specific examples thereof include serum, plasma, whole blood, urine, stool, saliva, ascites, oral mucosa, pharyngeal mucosa, intestinal mucosa, biopsy sample, and tissue staining of a test animal. Preferred is serum or plasma.
  • the biological sample may be a sample collected from a test animal or may have been subjected to pretreatment such as recovery, concentration, purification, isolation, dilution with a buffer solution, or filtration sterilization. These pretreatments may be appropriately performed according to a conventional method.
  • the test animal antibody to be measured may be an antibody against non-self or an autoantibody.
  • the target recognized by the antibody against the non-self is not particularly limited as long as it is a non-self having immunogenicity.
  • the non-self may be pathogenic.
  • pathogenic microorganisms include fungi, protozoans, bacteria, spirochete, rickettsia, chlamydia, mycoplasma, etc. that cause infectious diseases.
  • fungi such as Candida and Cryptococcus, malaria protozoa, diarrhea amoeba, vaginal trichomonas, pneumotiscarini pneumonia, protozoa such as Echinocox, gonorrhea, epidemic meningitis, staphylococci, streptococci, pneumonia diplococci, erythema. , Escherichia coli, Salmonella, Cholera, C. Chlamydia such as Riquetcia and Chlamydia trachomatis.
  • viruses examples include adenovirus, herpesvirus, papillomavirus, hepatitis virus, AIDS virus, hemp virus, influenza virus, coronavirus such as SARS-CoV-2, Japanese encephalitis virus, mad dog disease virus, norovirus, and rotavirus.
  • viruses include adenovirus, herpesvirus, papillomavirus, hepatitis virus, AIDS virus, hemp virus, influenza virus, coronavirus such as SARS-CoV-2, Japanese encephalitis virus, mad dog disease virus, norovirus, and rotavirus.
  • parasites include lung flukes, liver flukes, fasciola hepatica, Spirometra erinaceus, scab, filamentous worms, roundworms, Anisakis, jaw worms, fecal nematodes, and blood-sucking flukes.
  • the test animal antibody to be measured is preferably an antibody against a virus, and preferably an antibody against SARS-CoV-2.
  • the target recognized by the autoantibody is not particularly limited as long as it is a cell, tissue, or component existing in the living body of the autoantibody.
  • the target recognized by the autoantibody may be an antigen involved in an autoimmune disease. Examples of autoimmune diseases include rheumatoid arthritis, Hashimoto's disease, Based's disease (Graves' disease), antiphospholipid antibody syndrome, insulin autoimmune disease syndrome, scab, scab, scleroderma, Sjogren's syndrome, and Good Pasture's syndrome.
  • autoantibodies related to autoimmune diseases include anti-double-stranded DNA antibodies, anti-single-stranded DNA antibodies, anti-histon antibodies, anti-RNA antibodies, anti-RNP antibodies, anti-Sm antibodies, anti-SS-A antibodies, and anti-antibodies.
  • SS-B antibody anti-Scl-70 antibody, anti-PCNA antibody, anti-ribosome antibody, anti-mitochontic antibody, anti-centromea antibody, anti-immunoglobulin antibody, anti-tyroglobulin antibody, anti-thyroid peroxidase antibody, anti-microsome antibody, acetylcholine receptor antibody , Anti-erythrocyte antibody, anti-platelet antibody, anti-globulous basal membrane antibody, anti-Langerhans islet antibody, anti-adrenal cortex antibody, anti-gastric wall cell antibody and the like.
  • the antigen is an antigen that is recognized and bound by the test animal antibody to be measured. Therefore, the antigen is appropriately selected and used according to the test animal antibody to be measured.
  • the antigen can be prepared, for example, from cultured cells by a known method. Further, the protein antigen can be used as a recombinant protein by constructing an expression vector containing a DNA encoding a desired antigen protein using a known gene recombination technique, introducing the expression vector into an appropriate host cell, and culturing the vector. Can be prepared.
  • the DNA sequence encoding the desired antigenic protein can be obtained from a known database (such as NCBI).
  • the amino acid sequence of SARS CoV-2 spike protein has an accession number of "QHD43416.1", and the base sequence of the gene encoding this is the accession number "MN908947.3" at positions 21563 to 25384. ..
  • the antigen may be the full length of the protein antigen or a partial fragment (peptide).
  • protein antigens include full-length or partial fragments of viral proteins such as viral nucleocapsid protein (N protein), spike protein (S protein), S1 subunit, S2 subunit, and receptor-binding domain that make up the spike protein. Peptide).
  • the antigen and the biological sample of the test animal and the anti-test animal immunoglobulin antibody is performed, for example, in the presence of an appropriate buffer (antigen, biological sample of the test animal and anti-test animal immunoglobulin antibody).
  • an appropriate buffer antigen, biological sample of the test animal and anti-test animal immunoglobulin antibody.
  • the buffer solution include Tris buffer solution, phosphate buffer solution, acetate buffer solution, borate buffer solution, citrate buffer solution, veronal buffer solution and the like.
  • the antigen and the biological sample may be contacted first, and then the anti-test animal immunoglobulin antibody may be contacted, or the anti-test animal immunoglobulin antibody and the biological sample may be contacted first, and then the antigen is contacted.
  • the three parties may be brought into contact with each other at the same time.
  • the anti-test animal immunoglobulin antibody or antigen may be labeled with a labeling substance used for immunoassay.
  • An immobilized antigen may be used, or an immobilized anti-test animal immunoglobulin antibody may be used.
  • the immobilized support is not particularly limited as long as it is a normal support used for immunoassay, and is, for example, latex, rubber, polyethylene, polypropylene, polystyrene, styrene-butadiene copolymer, polyvinyl chloride, polyvinyl acetate, and the like.
  • Polymer materials such as polyacrylamide, polymethacrylate, styrene-methacrylate copolymer, polyglycidyl methacrylate, achlorine-ethylene glycol dimethacrylate copolymer, polyvinylidene difluoride (PVDF), silicone, silica gel, glass, inert alumina.
  • Inorganic materials such as magnetic materials are used.
  • the shape of the support is not particularly limited as long as it is the shape of a normal support used for immunoassay, and examples thereof include microplates, spheres, rods, and fine particles (beads).
  • Conditions such as the ratio of the antigen, the biological sample of the test animal to the anti-test animal immunoglobulin antibody, the contact time, the temperature, the pH, etc. are not particularly limited, and the test animal antibody to be measured, the measurement method to be used, and the use are used. It can be set as appropriate according to the measuring device and the like.
  • the temperature may be 0-37 ° C.
  • the pH may be pH 6-9
  • the contact time may be 1-120 minutes.
  • step 2 the complex of the antigen, the test animal antibody, and the anti-test animal immunoglobulin antibody is measured.
  • the measuring method is not particularly limited as long as it can detect and measure the complex.
  • the antigen and the biological sample are first contacted to form a complex of the antigen and the test animal antibody, and the anti-test animal immunoglobulin antibody labeled on the complex of the antigen and the test animal antibody is contacted and labeled.
  • Examples thereof include a method of measuring a complex of an antigen, a test animal antibody, and an anti-test animal immunoglobulin antibody by a measurement method according to a substance.
  • the anti-test animal immunoglobulin antibody and the biological sample are brought into contact with each other to form a complex of the anti-test animal immunoglobulin antibody and the test animal antibody, and then the anti-test animal immunoglobulin antibody and the test animal antibody are combined.
  • Examples thereof include a method in which a labeled antigen is brought into contact with the complex and a complex of the antigen, the test animal antibody and the anti-test animal immunoglobulin antibody is measured by a measurement method according to the labeling substance.
  • the labeling substance is not particularly limited, and can be appropriately selected and used from known labeling substances such as enzymes, fluorescent dyes, fluorescent proteins, radioactive isotopes, colloidal gold, biotin, and avidin.
  • enzymes include alkaline phosphatase (ALP), peroxidase (POD), microperoxidase, horse radish peroxidase (HRP), ⁇ -galactosidase ( ⁇ -gal) and the like
  • the fluorescent dye include fluorosane.
  • FITC fluorescein isothiocyanate
  • TAMRA tetramethyllodamine
  • TRICA tetramethyllodamine isothiocyanate
  • Texas red cyanine 3 (Cy3)
  • Cy5 cyanine 5
  • a method for measuring a labeling substance is known. For example, when an enzyme is used as a labeling substance, various measurements are performed depending on the substrate by adding a color-developing substrate, a fluorescent substrate, a chemically luminescent substrate, or the like as a substrate. be able to.
  • the measuring method of the present invention is characterized in that the anti-test animal immunoglobulin antibody uses a plurality of antibodies against a specific class of immunoglobulin. It is possible to improve the correlation between the measured value obtained by the measuring method of the present invention and the neutralizing activity value measured using the same biological sample. Multiple antibodies may be used in the form of a mixture.
  • Immunoglobulin antibodies are classified into five classes, IgG, IgM, IgA, IgD and IgE, depending on the type of heavy chain in the molecule, for example, in the case of human immunoglobulin antibodies.
  • the IgG molecule has a ⁇ chain as a heavy chain
  • IgM has a ⁇ chain
  • IgA has an ⁇ chain
  • IgE has an ⁇ chain
  • IgD has a ⁇ chain.
  • the test animal antibody to be measured may be any of IgG, IgM, IgA, IgD and IgE, and for detecting a plurality of antibodies against immunoglobulins of a specific class of test animals. It may be used as an antibody.
  • the particular class is preferably IgG or IgA with subclasses.
  • IgG has four subclasses of IgG1 to IgG4, and IgA has two subclasses of IgA1 and IgA2.
  • IgG is preferred for a particular class.
  • detection antibody used as anti-test animal immunoglobulin antibodies for detection may be monoclonal antibodies or polyclonal antibodies. It may be an antibody.
  • the antibody is a low-molecular-weight antibody to which an antibody fragment having an antigen-binding ability (for example, Fab, Fab', F (ab') 2 , Fv, scFv, diabody, etc.) and a variable portion of the antibody are bound. You may.
  • the detection antibody may be a combination of a plurality of monoclonal antibodies, a combination of one or more monoclonal antibodies and one or more polyclonal antibodies, or a combination of a plurality of polyclonal antibodies.
  • Polyclonal antibody and monoclonal antibody can be produced by known methods.
  • Polyclonal antibody immunizes mammals (mouse, rat, rabbit, goat, horse, etc.) using, for example, an antigen dissolved in PBS and optionally mixed with an appropriate amount of a usual adjuvant (for example, Freund's complete adjuvant) as an immunogen. It can be prepared by collecting blood from an immunized animal according to a conventional method, separating the serum, and purifying the polyclonal antibody fraction.
  • the immunization method is not particularly limited, but for example, a method of subcutaneous injection or intraperitoneal injection once or multiple times at appropriate intervals is preferable.
  • the monoclonal antibody can be produced, for example, by fusing immune cells (for example, splenocytes) obtained from the immunized mammal and myeloma cells to obtain a hybridoma, and collecting the antibody from the culture of the hybridoma. can. It is also possible to clone an antibody gene from a hybridoma, incorporate it into an appropriate vector, introduce it into a host cell, and use gene recombination technology to produce a recombinant monoclonal antibody. Furthermore, monoclonal antibodies can also be prepared using the phage display method. As the polyclonal antibody, for example, a polyclonal antibody excluding an antibody that reacts with a specific subclass by an adsorption treatment or the like may be used.
  • immune cells for example, splenocytes
  • the detection antibody preferably contains an antibody that cross-reacts with immunoglobulins of all subclasses of a specific class. That is, when the class of the test animal antibody to be measured is IgA, the detection antibody preferably contains a polyclonal antibody or a monoclonal antibody that binds to both IgA1 and IgA2, and the test animal to be measured preferably contains. When the antibody class is IgG, the detection antibody preferably comprises a polyclonal antibody or a monoclonal antibody that binds to all four subclasses of IgG1 to IgG4.
  • the polyclonal antibody or the monoclonal antibody cross-reacts with both IgA1 and IgA2, or cross-reacts with all four subclasses of IgG1 to IgG4.
  • Examples of the antibody that cross-reacts with all subclasses of immunoglobulin include the trade name Mouse Anti-Human IgG Fc-UNLB (Clone: JDC-10, manufactured by Southern Biotech). Recognition sites for antibodies that cross-react with all subclass immunoglobulins include the constant region and the Fc region.
  • Detection antibodies may include antibodies that cross-react with all subclass immunoglobulins of the particular class described above, as well as antibodies that specifically react with immunoglobulins of any one subclass of that particular class. preferable.
  • detection antibodies including antibodies that cross-react with both IgA1 and IgA2 and antibodies that specifically react with IgA1, and antibodies that cross-react with both IgA1 and IgA2 and are specific to IgA2. It is possible to select any of the detection antibodies including the antibody that reacts with the target.
  • detection antibodies that include the combinations shown below.
  • Detection antibody containing antibodies that cross-react with all subclasses of IgG and antibodies that specifically react with IgG1 (2) Antibodies that cross-react with all subclasses of IgG and antibodies that specifically react with IgG2 Detection antibody (3) Detection antibody containing antibody that cross-reacts with all subclasses of IgG and antibody that specifically reacts with IgG3 (4) Antibodies that cross-react with all subclasses of IgG and IgG4 specifically Detection antibody containing reactive antibody (5) Detection antibody containing antibody that cross-reacts with all subclasses of IgG, antibody that specifically reacts with IgG1 and antibody that specifically reacts with IgG2 (6) All of IgG Detection antibody including antibody that cross-reacts with the subclass of IgG1 and antibody that specifically reacts with IgG3 (7) Antibodies that
  • Detection antibody including antibody that reacts specifically with IgG3 and antibody that reacts specifically with IgG4 (11) Antibody that cross-reacts with all subclasses of IgG and antibody that reacts specifically with IgG1 and IgG2 specifically Detection antibody containing antibody that reacts specifically with IgG3 (12) Antibodies that cross-react with all subclasses of IgG, antibody that reacts specifically with IgG1, and antibody that reacts specifically with IgG2 Detection antibody containing antibody that specifically reacts with IgG4 (13) Antibodies that cross-react with all subclasses of IgG, antibodies that specifically react with IgG1, antibodies that specifically react with IgG3, and IgG4.
  • Antibodies that cross-react with all subclasses of IgG antibodies that specifically react with IgG2, antibodies that specifically react with IgG3, and antibodies that react specifically with IgG4. Included detection antibodies (15) Antibodies that cross-react with all subclasses of IgG, antibodies that specifically react with IgG1, antibodies that specifically react with IgG2, antibodies that specifically react with IgG3, and IgG4 specifically.
  • Anti-antibody Detection antibody including corresponding antibody
  • Antibodies that specifically react with immunoglobulins of any one subclass of a specific class include, for example, IgG1 such as the trade name Mouse anti-Human IgG1 Fc Secondary Antibody (Clone: HP6070, manufactured by Thermo Fisher Scientific). Antibodies that specifically react with IgG2, trade name Mouse monoclonal [31-7-4] Anti-Human IgG2 Fc (Clone: 31-7-4, manufactured by Abcum), etc.
  • IgG1 such as the trade name Mouse anti-Human IgG1 Fc Secondary Antibody (Clone: HP6070, manufactured by Thermo Fisher Scientific).
  • Antibodies that specifically react with IgG2 trade name Antibodies that specifically react with IgG3 such as Mouse Anti-Human IgG3 Hinge-UNLB (Clone: HP6050, manufactured by Southern Biotech), trade name Mouse Anti-Human IgG4 Fc-UNLB (Clone: HP6025, manufactured by Southern Biotech), Product name: Mouse Anti-Human IgG4 pFc'-UNLB (Clone: HP6023, manufactured by Southern Biotech), Monoclonal Antibody to Human IgG4 (Clone: 5C3, manufactured by Yamasa Soy Sauce) and other antibodies that specifically react with IgG4. Be done.
  • the recognition site of the antibody that specifically reacts with the immunoglobulin of any one subclass of the specific class include a constant region, an Fc region, a pFc'region, a hinge region, and the like.
  • the detection antibody may include a plurality of antibodies that specifically react with a specific subclass of immunoglobulin.
  • each antibody is preferably an antibody that recognizes different epitopes of that subclass of immunoglobulin.
  • an antibody that specifically reacts with the immunoglobulin of each subclass may be used in combination. That is, in the case of IgA, it may be a detection antibody containing an antibody that specifically reacts with IgA1 and an antibody that specifically reacts with IgA2, and in the case of IgG, an antibody that specifically reacts with IgG1 and IgG2 may be used. It may be a detection antibody containing an antibody that specifically reacts with IgG3, an antibody that specifically reacts with IgG3, and an antibody that specifically reacts with IgG4. An antibody that specifically reacts with immunoglobulin of any one or more subclasses may be added to the detection antibody having such a configuration to obtain a detection antibody.
  • the method for measuring the complex of the antigen, the test animal antibody, and the anti-test animal immunoglobulin antibody in step 2 include, for example, an enzyme-bound immunoassay measurement method (ELISA method) and an enzyme immunoassay.
  • the correlation between the measured value of the test animal antibody to be measured and the neutralizing antibody is compared with the measurement method using a single detection antibody (anti-test animal immunoglobulin antibody). It can enhance sex.
  • the evaluation method of the neutralizing antibody activity (neutralizing activity) differs depending on the antigen recognized by the test animal antibody to be measured, and a known neutralizing activity value measuring method is used depending on the antigen recognized by the test animal antibody. Can be measured.
  • kits of the present invention provide a kit for measuring a test animal antibody contained in a biological sample of a test animal (hereinafter referred to as "kit of the present invention").
  • kit of the present invention a plurality of reagents containing an anti-test animal immunoglobulin antibody for detecting an antibody of a test animal to be measured (hereinafter referred to as "antibody reagent for detection") are used for a specific class of immunoglobulin. It is characterized by being an antibody of.
  • the detection antibody reagent provides the detection antibody described above as a reagent.
  • the detection antibody reagent is a combination of a plurality of antibodies as described above, and may be a reagent in which a mixture of a plurality of antibodies is provided in one container, or a form in which the plurality of antibodies are provided in separate containers. It may be used as a reagent of.
  • the antibody contained in the detection antibody reagent may be labeled.
  • the detection antibody reagent can be prepared, for example, by dissolving the antibody in a buffer solution suitable for the antibody solution. When the reagent is in the form of a mixture, it can be prepared by mixing each antibody solution.
  • a Tris buffer solution having a pH of 6 to 9, preferably a pH of 7 to 8, a phosphate buffer solution, an acetate buffer solution, a borate buffer solution, a citrate buffer solution, a veronal buffer solution and the like can be used. ..
  • the detection antibody reagent may be freeze-dried.
  • the kit of the present invention may include a reagent containing an antigen recognized by the test animal antibody to be measured (hereinafter referred to as "antigen reagent") in addition to the detection antibody reagent. Since the antigen varies depending on the test animal antibody to be measured, a kit containing the desired antigen reagent is individually provided.
  • the antigen may be labeled.
  • the antigen reagent can be prepared, for example, by dissolving the antigen in a buffer solution suitable for the antigen solution. Examples of the buffer solution suitable for the antigen solution include those similar to the buffer solution suitable for the antibody reagent for detection.
  • the antigen reagent may be freeze-dried.
  • the full length or fragment of the SARS CoV-2 spike protein can be used as the antigen.
  • the full length or fragment of the SARS CoV-2 spike protein can be produced as a recombinant protein using known gene recombination techniques.
  • the kit of the present invention may contain a buffer solution for diluting a sample, reagents for measuring a labeling substance, a multi-well plate or tube, instructions for use, and the like.
  • Example 1 Measurement of IgG antibody against SARS-CoV-2 S-RBD in COVID-19 patients
  • S-RBD SARS-CoV-2 Spike protein receptor binding domain
  • MES 2-morpholinoetan sulfonic acid, manufactured by Dojin Chemical Industries, Ltd.
  • sodium chloride manufactured by Dojin Chemical Industries, Ltd.
  • BSA manufactured by Sigma Aldrich Japan Co., Ltd.
  • boric acid manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.
  • Luminor sodium salt manufactured by Sigma Aldrich Japan Co., Ltd.
  • Phosphoric acid manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.
  • Hydrogen peroxide manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.
  • Magnetic silica particles (trade name: Magrapid, manufactured by Sanyo Kasei Kogyo Co., Ltd.) are reacted with ⁇ -aminopropyltriethoxysilane (manufactured by Shin-Etsu Chemical Co., Ltd.) and anhydrous professioncinic acid (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) one after another. Then, the particles were collected by a neodymium magnet and the supernatant was removed to obtain magnetic particles having a carboxyl group.
  • Second reagent (reaction buffer) A buffer solution having the following composition was prepared. ⁇ 50mM MES (pH 6.0) ⁇ 300 mM sodium chloride
  • Reagent A Antibodies that recognize all subclasses of human IgG (hereinafter referred to as "anti-human IgG antibodies”)
  • Reagent B An antibody that specifically recognizes human IgG4 (hereinafter referred to as "anti-human IgG4 antibody”)
  • Reagent C Mixing of anti-human IgG antibody and anti-human IgG4 antibody
  • COVID-19 ELISA reagent (trade name: COVID-19 IgG test ELISA kit Wako (S-RBD), manufactured by Fujifilm Wako Junyaku Co., Ltd.) for the enzyme-labeled anti-human IgG antibody of the third reagent A and the third reagent C.
  • the enzyme-labeled antibody included in the kit was diluted and used.
  • the enzyme-labeled antibody included in this kit is an antibody that recognizes all subclasses of human IgG.
  • Reagent C having the following composition was prepared by mixing the third reagent A and the antibody used in the third reagent B. ⁇ 53.3% enzyme-labeled anti-human IgG antibody solution ⁇ 1000ppm POD-labeled anti-human IgG4 antibody (diluted 1000 times) ⁇ 50mM MES (pH 6.5) ⁇ 150 mM sodium chloride ⁇ 2.0% BSA
  • the reaction cuvette 50 ⁇ L of the first reagent added to the reaction cuvette is magnetized using a neodymium magnet, the supernatant is removed, and then 140 ⁇ L of the second reagent and 10 ⁇ L of the measurement sample (COVID-19 patient serum or calibration curve sample) are added. The mixture was stirred and heated at 37 ° C. for 3 minutes. After the heating was completed, magnetism was collected using a neodymium magnet, reagents other than magnetic particles were removed, and the mixture was washed 3 times with a washing solution. Subsequently, 50 ⁇ L of the third reagent was added, and the mixture was heated at 37 ° C. for 3 minutes.
  • FIG. 1 shows the correlation between the antibody concentration and the neutralization activity value.
  • A is the result when the third reagent A is used
  • B is the result when the third reagent B is used
  • C is the result when the third reagent C is used. An improvement in correlation was observed when the third reagent C was used as compared with the case where the third reagent A or the third reagent B was used.
  • Example 2 Measurement of IgG antibody against SARS-CoV-2 S-RBD in COVID-19 patients
  • Anti-human IgG3 antibody an antibody that specifically recognizes human IgG3 (hereinafter referred to as "anti-human IgG3 antibody”) instead of the anti-human IgG4 antibody used in the third reagents B and C of Example 1.
  • POD-labeled anti-human IgG3 antibody (Clone: HP6050, manufactured by Southern Biotech) was used to prepare a third reagent D containing only the anti-human IgG3 antibody and a third reagent E containing the anti-human IgG antibody and the anti-human IgG3 antibody. did.
  • the composition of the third reagent D is as follows. ⁇ 100ppm POD-labeled anti-human IgG3 antibody (10000-fold diluted) ⁇ 50mM MES (pH 6.5) ⁇ 150 mM sodium chloride ⁇ 2.0% BSA
  • the composition of the third reagent E is as follows. ⁇ 53.3% enzyme-labeled anti-human IgG antibody solution ⁇ 100ppm POD-labeled anti-human IgG3 antibody (10000-fold diluted) ⁇ 50mM MES (pH 6.5) ⁇ 150 mM sodium chloride ⁇ 2.0% BSA
  • SARS-CoV was used for 34 COVID-19 patient sera by the same method as in Example 1 except that the third reagent D was used instead of the third reagent B and the third reagent E was used instead of the third reagent C.
  • the antibody concentration against S-RBD and the neutralization activity value against SARS-CoV-2 were measured.
  • the third reagent D since it is not possible to prepare a calibration curve with a sample for a calibration curve, a study was conducted using the calibration curve prepared with the third reagent A.
  • FIG. 2 shows the correlation between the antibody concentration and the neutralization activity value.
  • A is the result when the third reagent A is used
  • B is the result when the third reagent D is used
  • C is the result when the third reagent E is used. An improvement in correlation was observed when the third reagent E was used as compared with the case where the third reagent A or the third reagent D was used.
  • Example 3 Measurement of IgG antibody against SARS-CoV-2 Spike protein in COVID-19 patients
  • S-full Immobilization Plate 3-1 Reagents and Methods SARS-CoV-2 Spike protein Immobilization Plate (hereinafter referred to as "S-full Immobilization Plate") and COVID-19 ELISA Reagent (trade name: COVID-19 IgG Test ELISA Kit Wako (S) -RBD), manufactured by Fujifilm Wako Junyaku Co., Ltd.) to measure the amount of IgG antibody against SARS-CoV-2 Spike protein in the sera of 34 sera collected from COVID-19 patients who visited Fujita Medical University. The patient's serum was compared with the neutralizing activity value for COVID-19.
  • the enzyme-labeled antibody included in this kit is an antibody that recognizes all subclasses of human IgG.
  • SARS-CoV-2 Spike protein manufactured by CerTest
  • 50 mM carbonate buffer was reacted with a 96-well plate (manufactured by Thermo Fisher Scientific Co., Ltd.) to block 1.0%.
  • An S-full immobilized plate was prepared by blocking with a phosphate buffer solution containing Ace (manufactured by KAC Co., Ltd.).
  • FIG. 3 shows the correlation between the amount of IgG antibody against S-full calculated above and the neutralizing activity value measured in Example 1.
  • (A) is the result of evaluating the third reagent A
  • (B) is the result of evaluating the third reagent E.
  • Both the antibody that recognizes all subclasses of anti-human IgG and the anti-human IgG3 antibody (third reagent E) are compared with the case where the antibody that recognizes all subclasses of anti-human IgG alone (third reagent A) is used. When used, improvement in correlation was observed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
PCT/JP2021/044427 2020-12-04 2021-12-03 抗体を測定する方法およびキット Ceased WO2022118947A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022566997A JPWO2022118947A1 (https=) 2020-12-04 2021-12-03

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-202321 2020-12-04
JP2020202321 2020-12-04

Publications (1)

Publication Number Publication Date
WO2022118947A1 true WO2022118947A1 (ja) 2022-06-09

Family

ID=81853411

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/044427 Ceased WO2022118947A1 (ja) 2020-12-04 2021-12-03 抗体を測定する方法およびキット

Country Status (2)

Country Link
JP (1) JPWO2022118947A1 (https=)
WO (1) WO2022118947A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024029523A1 (ja) * 2022-08-02 2024-02-08 応用酵素医学研究所株式会社 コロナウイルス感染症の評価項目を判断するための情報を提供する方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5531995A (en) * 1978-08-24 1980-03-06 Akzo Nv Method of measuring quantity of immunizing globulin
JPS60177265A (ja) * 1984-02-24 1985-09-11 Japan Synthetic Rubber Co Ltd 抗体の免疫グロブリンのクラス別検出法
JPS6336150A (ja) * 1986-07-30 1988-02-16 Denka Seiken Co Ltd 特定免疫グロブリン種抗体の定量方法
JP2006126202A (ja) * 2004-10-30 2006-05-18 F Hoffmann La Roche Ag 抗原特異的に結合した特定の免疫グロブリンクラスの抗体を検出する際に、アレイ試験方式においてブランク値を低減するための免疫複合体特異的抗体
JP2006520896A (ja) * 2003-03-10 2006-09-14 ティーシーピー イノベーションズ リミテッド イムノアッセイ
JP2018524585A (ja) * 2015-07-10 2018-08-30 シュ デ ニース Ｐｌａ２ｒ１エピトーププロファイルおよびｐｌａ２ｒ１エピトープスプレッディングの分析に基づく膜性腎症の予後およびモニタリング
JP2020515826A (ja) * 2016-11-25 2020-05-28 オンシミューン リミテッド 抗体アッセイ

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5531995A (en) * 1978-08-24 1980-03-06 Akzo Nv Method of measuring quantity of immunizing globulin
JPS60177265A (ja) * 1984-02-24 1985-09-11 Japan Synthetic Rubber Co Ltd 抗体の免疫グロブリンのクラス別検出法
JPS6336150A (ja) * 1986-07-30 1988-02-16 Denka Seiken Co Ltd 特定免疫グロブリン種抗体の定量方法
JP2006520896A (ja) * 2003-03-10 2006-09-14 ティーシーピー イノベーションズ リミテッド イムノアッセイ
JP2006126202A (ja) * 2004-10-30 2006-05-18 F Hoffmann La Roche Ag 抗原特異的に結合した特定の免疫グロブリンクラスの抗体を検出する際に、アレイ試験方式においてブランク値を低減するための免疫複合体特異的抗体
JP2018524585A (ja) * 2015-07-10 2018-08-30 シュ デ ニース Ｐｌａ２ｒ１エピトーププロファイルおよびｐｌａ２ｒ１エピトープスプレッディングの分析に基づく膜性腎症の予後およびモニタリング
JP2020515826A (ja) * 2016-11-25 2020-05-28 オンシミューン リミテッド 抗体アッセイ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FUJIGAKI HIDETSUGU, TAKEMURA MASAO, OSAWA MICHIKO, FUJITA TAKASHI, MIZUTANI KENMEI, SAKAI YOSHIMI, DOI YOHEI, AKIYAMA HIDEHIKO, HA: "Evaluation of VITROS Anti-SARS CoV-2 IgG Assay with VITROS 5600 II Integrated System", JAPANESE JOURNAL OF MEDICINE AND PHARMACEUTICAL SCIENCE, vol. 78, no. 3, 1 January 2021 (2021-01-01), JP , pages 281 - 288, XP009537119, ISSN: 0389-3898 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024029523A1 (ja) * 2022-08-02 2024-02-08 応用酵素医学研究所株式会社 コロナウイルス感染症の評価項目を判断するための情報を提供する方法

Also Published As

Publication number Publication date
JPWO2022118947A1 (https=) 2022-06-09

Similar Documents

Publication Publication Date Title
AU2016203292B2 (en) Monoclonal antibody, and immunoassay using same
JP7105970B1 (ja) ＳＡＲＳ－ＣｏＶ－２の免疫測定方法及び免疫測定キット
WO2022193980A1 (zh) 针对新型冠状病毒核衣壳蛋白的抗体或其抗原结合片段及其应用
JP2009085753A (ja) サンドイッチイムノアッセイ法
WO2022265065A1 (ja) ＳＡＲＳ－ＣｏＶ－２の免疫測定方法及び免疫測定キット、並びにモノクローナル抗体又はその抗体断片
JP6867529B1 (ja) ヘリコバクター・ピロリ検出用抗体
JPWO2016136918A1 (ja) 免疫学的測定方法及び該方法に用いられる測定試薬
JP7315966B2 (ja) 生物学的試料中の遊離ａｉｍの免疫学的分析方法
WO2007003090A1 (fr) Composition remplaçant un sérum positif utilisée comme témoin dans un agent de diagnostic et application de celle-ci
US12265083B2 (en) Immunoassay method for free AIM in biological sample, and assay kit
JP2009222712A (ja) メチシリン耐性ブドウ球菌の検出法、検出用試薬及び検出用キット
JPWO2016136863A1 (ja) Ｌ−ｆａｂｐの免疫学的測定方法及び該方法に用いられる測定試薬
CN109069600A (zh) Il-21抗体及其用途
WO2022118947A1 (ja) 抗体を測定する方法およびキット
WO2020158858A1 (ja) 生物学的試料中の遊離ａｉｍの免疫学的分析方法及び対象におけるｎａｓｈの検出方法
US20240302366A1 (en) Immunological assay method
JP7055715B2 (ja) ジカウイルス抗原および抗ジカウイルス抗体を検出するための方法およびキット
JP7722772B2 (ja) 敗血症原因細菌の免疫学的分析キット
JP2000266748A (ja) 抗マウスＩｇＥ抗体を用いたマウスＩｇＥの測定キット及び測定方法
CN108713141A (zh) 用于定量生物试样中的测定对象物质的试剂盒
JP2025024795A (ja) 抗体又は抗原結合性断片－基材複合体
Michael et al. Immuno-diagnosis of some microbial antigens and antibodies using dissociated immune complexes and serum: A comparative study
JP2019210211A (ja) ウシプロカルシトニンを特異的に認識する抗体、その抗原結合断片、および、その使用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21900696

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022566997

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21900696

Country of ref document: EP

Kind code of ref document: A1